Free shipping on all orders over $ 500


Cat. No. M2081
LY2109761 Structure
Size Price Availability Quantity
5mg USD 75  USD75 In stock
10mg USD 135  USD135 In stock
50mg USD 420  USD420 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

LY2109761 is a Transforming Growth Factor β (TGF-β) type I /II receptor (TβRI/TβRII) kinase inhibitor with Ki of 38 nM and 300 nM, respectively. LY2109761 significantly inhibited the L3.6pl/GLT soft agar growth, suppressed both basal and TGF-beta1-induced cell migration and invasion, and induced anoikis. LY2109761 reduced clonogenicity and increased radiosensitivity in GBM cell lines and cancer stem-like cells, augmenting the tumor growth delay produced by fractionated radiotherapy in a supra-additive manner in vivo. In addition, LY2109761 had antimigratory and antiangiogenic effects in Matrigel migration and tube formation assays. LY2109761 also reduced tumor blood perfusion as quantified by noninvasive dynamic contrast-enhanced magnetic resonance imaging. In an orthotopic intracranial model, LY2109761 significantly reduced tumor growth, prolonged survival, and extended the prolongation of survival induced by radiation treatment. In vivo, in human xenograft tumors growing subcutaneously on BALB/c nu/nu mice, LY2109761 delayed tumor growth alone and in combination with fractionated radiation and TMZ.

Product Citations
Customer Product Validations & Biological Datas
Source Dissertaion (2015). Figure 3.5. LY2109761 was obtained from abmole (AbMole, Houston, TX).
Method western blot
Cell Lines mesenchymal/stem cell tumor
Concentrations 50mg/kg LY2109761 twice every day
Incubation Time two weeks
Results LY2109761 significantly decreased the expression levels of ZEB2, VCAN, THY1, CDK6, SOX2 and GLI2, even in the presence of TMZ/IR, demonstrating the key role of the TGF-β signaling pathway in regulating mesenchymal and stem cells markers.
Protocol (for reference only)
Cell Experiment
Cell lines Colo357FG/GLT and Colo357L3.6pl/GLT cells
Preparation method LY2109761 was dissolved in 100% DMSO at a stock concentration of 10 mmol/L. The concentration of DMSO did not exceed 0.1% in any assay. FG/GLT nonmetastatic pancreatic carcinoma cells (A) and their highly metastatic subclone L3.6pl/GLT pancreatic carcinoma cells were seeded at a density of 1.0 × 103 per well. On the following day, the cells were treated with increasing doses of LY2109761 (0.1, 1, and 10 μmol/L), gemcitabine (0.3, 3,and 30 nmol/L), and their combinations. On day 2, the medium containing drugs was removed, the cells were washed twice with PBS, and fresh medium was added. After 5 d of incubation, the 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was used to obtain relative variable cell numbers. DMSO-treated cells were assigned a value of 100%. Means and 95% confidence intervals of three independent experiments performed in triplicate.
Concentrations 0, 2, 20 µ M
Incubation time 5 days
Animal Experiment
Animal models Human Pancreatic Carcinoma Tumors Growing in the Pancreas of Athymic Nude Mice
Formulation dissolved in the SX-1292 oral vehicle (1% sodium carboxymethylcellulose, 0.5% sodium lauryl sulfate, and 0.05% antifoam; Eli Lilly)
Dosages LY2109761 (50 mg/kg) twice a day p.o. (days 1–5 of each week)
Administration p.o.
Chemical Information
Molecular Weight 441.52
Formula C26H27N5O2
CAS Number 700874-71-1
Solubility (25°C) DMSO 20 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Zhang M, et al. Cancer Res. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.

[2] Zhang M, et al. Neoplasia. Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761.

[3] Melisi D, et al. Mol Cancer Ther. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.

Related TGF-β Receptor Products
LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA)

LSKL, Inhibitor of Thrombospondin (TSP-1) TFA is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist.

LSKL, Inhibitor of Thrombospondin (TSP-1)

LSKL, Inhibitor of Thrombospondin (TSP-1) is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist.


KRFK TFA is a peptide derived from TSP-1, which can activate TGF-β.

Maohuoside A

Maohuoside A potently promotes osteogenesis. Maohuoside A enhances the osteogenesis of bone marrow-derived mesenchymal stem cells via bone morphogenetic protein (BMP) and MAPK signaling pathways


Vicatertide is a TGF beta-1 inhibitor.

Abmole Inhibitor Catalog

Keywords: LY2109761 supplier, TGF-β Receptor, inhibitors, activators

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.